Article
Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race.
Pharmacogenetics and genomics - 1 Oct 2016
Leger Paul, Chirwa Sanika, Turner Megan, Richardson Danielle M, Baker Paxton, Leonard Michael, Erdem Husamettin, Olson Lana, Haas David W
Abstract excerpt
BACKGROUND: Efavirenz frequently causes central nervous system (CNS) symptoms. We evaluated genetic associations with efavirenz discontinuation for CNS symptoms within 12 months of treatment initiation. METHODS: Patients had initiated efavirenz-containing regimens at an HIV primary care clinic in the Southeastern United States and had at least 12 months of follow-up data. Polymorphisms in CYP2B6 and CYP2A6...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.